Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 29, 2024 5:53pm
237 Views
Post# 36153380

Private Placement

Private Placement Wow, what can I say. Raising $600K now when share price is at $1.50. The share price is down 30% in the past year, this could have and should have been done at a higher valuation. They did a similar raise 3 years ago I believe. Compare the company 3 years ago to the company today. Unfortunately they appear desperate.

There is nothing positive on this in my opinion. 

The only interesting aspect is the 4 month lockup period that prevents participants from selling their shares for a 4 month period. That takes us to December. There must be some reason Management negotiated this into the contract.

This company continues to march at its own tune and operates completely opposite of many of its peers. To me that is a head scratcher and might explain why our similar staged peers have 25%++ institutional ownership and much higher market caps.
<< Previous
Bullboard Posts
Next >>